about
The fate of medications evaluated for ischemic stroke pharmacotherapy over the period 1995-2015Bleeding related to disturbed fibrinolysisEffect of Fagonia Arabica (Dhamasa) on in vitro thrombolysis.Targeted thrombolysis strategies for neuroprotective effectTenecteplase for treatment of acute myocardial infarction.Immunotargeting of collagenase on thrombusCholesterol embolization syndrome: cutaneous histopathological features and the variable onset of symptoms in patients with different risk factors.Pharmacological interventions for stroke: failures and future.Effects of organic extracts and their different fractions of five Bangladeshi plants on in vitro thrombolysisTreatments for stroke.Antithrombotic Effects of Five Organic Extracts of Bangladeshi Plants In Vitro and Mechanisms in In Silico Models.Fibrin(ogen)-independent role of plasminogen activators in acetaminophen-induced liver injuryAdvances in revascularization for acute ischemic stroke treatment.Understanding the enzymology of fibrinolysis and improving thrombolytic therapy.Activity Regulation by Fibrinogen and Fibrin of Streptokinase from Streptococcus Pyogenes.Advances in thrombolytics and mechanical devices for treatment of acute ischemic stroke.Endovascular management of acute ischemic stroke: advances in patient and treatment selection.Effects of Five Bangladeshi Plant Extracts on In vitro Thrombolysis and Cytotoxicity.Advances in revascularization for acute ischemic stroke treatment: an update.Serine-proteases as plasminogen activators in terms of fibrinolysis.Clinical trials in acute ischemic stroke.Enzyme promiscuity in earthworm serine protease: substrate versatility and therapeutic potential.Edaravone (Radicut), a free radical scavenger, is a potentially useful addition to thrombolytic therapy in patients with acute ischemic stroke.Thrombolysis for Massive Pulmonary Embolism in Pregnancy.Recent advances in targeted delivery of tissue plasminogen activator for enhanced thrombolysis in ischaemic stroke.Intra-arterial third-generation recombinant tissue plasminogen activator (reteplase) for acute ischemic stroke.Understanding haemorrhagic risk following thrombolytic therapy in patients with intermediate-risk and high-risk pulmonary embolism: a hypothesis paper.Earthworm Protease
P2860
Q28069442-78265BBB-E9BB-4B66-A12D-F5598E377F9FQ28070127-11D845C9-9E5C-48C8-8FCF-19706E77D685Q33305135-6D89A6CC-7A0F-494E-B8F6-03FF8EDF4CE7Q34163191-3D20CAC5-53FF-4B9A-AFC9-3898AE8FD79CQ34417294-1CCF5353-92FA-45FC-9698-81BD2C403CE9Q34440046-470373BF-66BD-4D32-9D7F-4B2A26A0B89CQ34600496-4F2D4353-0173-43B0-A4E1-60E60EEDD7BFQ34628650-895F89B9-E270-47AD-AB33-9EB19FD7451FQ35552297-91565C69-98E8-4B94-8A97-29208445F8C0Q35581150-573951BC-4BE5-4B57-BD25-EAC826CA7791Q35667939-FCBDD357-362D-4A6B-A82C-0D3E8FE4F054Q36044653-26C6A83D-442B-4369-87C7-57E97DBCCC0AQ36106802-3262EDC6-2A08-4B40-BD98-8EE4978EB6D1Q36156022-D04391E9-652A-43ED-AE9C-D0E084E7B378Q36261579-F2E1C674-C479-44B1-A17F-F46EE57327A0Q36273735-ACEA00B3-DEED-4FB2-A30B-018B4B031547Q36730655-265CF270-ED3D-4C51-A23D-721FA0CA7072Q37006922-3CEB9095-ABD7-493F-AF7B-3D975D3533FBQ37907291-CD9DCE00-17A1-4AA8-B641-D88B2B14E8C9Q38024834-9A31B101-FB59-44AB-A59A-E2A063C0E227Q38243696-8C51CDDA-653D-4BB2-A90F-3480DED201D2Q38688962-698C50B7-A8BB-4162-8168-E59B1FB529D8Q42408578-7CB2207B-B314-41DA-B8A9-4B1A3E7F4516Q48005364-7D852057-34ED-4F40-8EA6-C26C10135678Q48159250-35C5465B-1F4A-415F-8FBA-4C6E0C501306Q48821499-20B21313-1DA4-4238-9CDB-39B7C0C6FA97Q52659266-AC21BAC4-C046-49D8-B608-9ED27DF36AE3Q58650317-6F4A9A74-4AC5-4202-936F-88A27AFC2464
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Third-generation thrombolytic drugs.
@ast
Third-generation thrombolytic drugs.
@en
type
label
Third-generation thrombolytic drugs.
@ast
Third-generation thrombolytic drugs.
@en
prefLabel
Third-generation thrombolytic drugs.
@ast
Third-generation thrombolytic drugs.
@en
P1476
Third-generation thrombolytic drugs.
@en
P2093
Verstraete M
P356
10.1016/S0002-9343(00)00380-6
P407
P577
2000-07-01T00:00:00Z